Literature DB >> 19513627

Correlation and expression of COX-2 and P53 protein in basal cell carcinoma of eyelid.

Zhixiong Chen1, Jiong Yang, Qiong Huang.   

Abstract

The correlation between the expression of COX-2 and p53 protein in basal cell carcinoma (BCC) of eyelid and apoptosis was investigated. Specimens of BCC were collected from 40 cases (aged 28-68 y) at the Department of Pathology, Renmin Hospital of Wuhan University, and Department of Pathology, Zhongnan Hospital of Wuhan University during from 1999 to 2006. Five specimens of paracancerous tissues served as control group. Immunohistochemical staining was performed to detect the expression of COX-2 and p53 in the tissues. The average absorbance (A) and the average positive area rate of COX-2 and p53 protein were measured by image analysis. The positive area rate of COX-2 and p53 protein was analyzed by linear correlation analysis. It was found that COX-2 and p53 proteins were highly expressed in BCC of eyelid, and weakly expressed in paracancerous tissues. Image analysis revealed that the expression of COX-2 and p53 proteins in BCC of eyelid was significantly higher than that in paracancerous tissues (P<0.01). Spearman rank correlation analysis demonstrated a positive correlation between the expression of COX-2 and p53 (r=0.113, P=0.421). It was concluded that COX-2 can increase the expression of p53 protein, therefore suppressing apoptosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19513627     DOI: 10.1007/s11596-009-0324-9

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  12 in total

1.  Gorlin syndrome: the PTCH gene links ocular developmental defects and tumour formation.

Authors:  N K Ragge; A Salt; J R O Collin; A Michalski; P A Farndon
Journal:  Br J Ophthalmol       Date:  2005-08       Impact factor: 4.638

Review 2.  COX-2 inhibitors in cancer treatment and prevention, a recent development.

Authors:  Xiao-Chun Xu
Journal:  Anticancer Drugs       Date:  2002-02       Impact factor: 2.248

3.  Polymorphism in the nuclear factor kappa-B binding promoter region of cyclooxygenase-2 is associated with an increased risk of bladder cancer.

Authors:  Sokbom Kang; Yong Beom Kim; Moon-Hong Kim; Kyung-Sik Yoon; Jae Weon Kim; Noh Hyun Park; Yong Sang Song; Daehee Kang; Keun-Young Yoo; Soon Beom Kang; Hyo Pyo Lee
Journal:  Cancer Lett       Date:  2005-01-10       Impact factor: 8.679

4.  Aberrant p53 expression correlates with expression of vascular endothelial growth factor mRNA and interleukin-8 mRNA and neoangiogenesis in non-small-cell lung cancer.

Authors:  Ang Yuan; Chong-Jen Yu; Kwen-Tay Luh; Sow-Hsong Kuo; Yung-Chie Lee; Pan-Chyr Yang
Journal:  J Clin Oncol       Date:  2002-02-15       Impact factor: 44.544

Review 5.  Basal cell carcinomas of the eyelids.

Authors:  J Allali; F D'Hermies; G Renard
Journal:  Ophthalmologica       Date:  2005 Mar-Apr       Impact factor: 3.250

6.  Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II study.

Authors:  M Schuler; R Herrmann; J L De Greve; A K Stewart; U Gatzemeier; D J Stewart; L Laufman; R Gralla; J Kuball; R Buhl; C P Heussel; F Kommoss; A P Perruchoud; F A Shepherd; M A Fritz; J A Horowitz; C Huber; C Rochlitz
Journal:  J Clin Oncol       Date:  2001-03-15       Impact factor: 44.544

7.  Lysosomal destabilization in p53-induced apoptosis.

Authors:  Xi-Ming Yuan; Wei Li; Helge Dalen; Joseph Lotem; Rachel Kama; Leo Sachs; Ulf T Brunk
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-16       Impact factor: 11.205

8.  p53 triggers apoptosis in oncogene-expressing fibroblasts by the induction of Noxa and mitochondrial Bax translocation.

Authors:  M Schuler; U Maurer; J C Goldstein; F Breitenbücher; S Hoffarth; N J Waterhouse; D R Green
Journal:  Cell Death Differ       Date:  2003-04       Impact factor: 15.828

Review 9.  COX-2 - a target for preventing hepatic carcinoma?

Authors:  Mohammad A Rahman; Hitoshi Kohno; Naofumi Nagasue
Journal:  Expert Opin Ther Targets       Date:  2002-08       Impact factor: 6.902

10.  Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer.

Authors:  N K Altorki; R S Keresztes; J L Port; D M Libby; R J Korst; D B Flieder; C A Ferrara; D F Yankelevitz; K Subbaramaiah; M W Pasmantier; A J Dannenberg
Journal:  J Clin Oncol       Date:  2003-07-15       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.